Applied Genetic Technologies Corporation has received written feedback from the FDA about its potential X-linked retinitis pigmentosa treatment and updated its development plan accordingly, according to a press release.
The feedback focused mostly on the design and execution of a registration trial and future submissions. AGTC is conducting clinical trials of adeno-associated virus-based gene therapies for rare diseases, including X-linked retinitis pigmentosa (XLRP).
“We are pleased with the productive feedback from the FDA and are modifying our development program based on their
Uncategorized